What is acute myeloid leukemia? Acute myeloid leukemia (AML), also spelled leukaemia, is a fast-developing cancer of blood and bone marrow involving abnormal immature myeloid cells. NCI AML description.
Confidence: high for the need for prompt specialist assessment and a specific laboratory diagnosis. This adult care overview explains pathways and urgent concerns. It does not independently establish drug superiority, interpret a personal blood result or supply a childhood treatment protocol.
- AML needs prompt assessment; a symptom checklist cannot identify the subtype.
- Blood and marrow findings guide the final diagnosis.
- APL is a distinct AML subtype with urgent bleeding and clotting concerns.
- Treatment-period infection signs require prompt contact with the cancer team.
- No supplement replacement benefit is independently established in this review.
Table of contents
- Evidence summary
- What AML is: abnormal myeloid cells in blood and marrow
- Symptoms: rapid change requires clinical assessment
- Diagnosis: confirm the cells before selecting a pathway
- Acute promyelocytic leukemia: a distinct urgent subtype
- Treatment families: intensity and purpose are individual decisions
- Infection, neutropenia and urgent treatment-period concerns
- Interactions: check actual drugs, foods and ingredients
- Supportive care, nutrition and symptom relief
- Disease status and follow-up: ask what the next result means
- Supplements and laboratory findings: what the review establishes
- Funding and source roles
- Frequently asked questions
- Sources and funding notes
Evidence summary
Clinical descriptions, care guidance and independently established treatment outcomes have different evidentiary roles. The table identifies what the reviewed sources can support and which financial or clinical questions remain unresolved.
| Question / approach | Evidence reviewed | Funding / conflicts | Interpretation / limits |
|---|---|---|---|
| Disease recognition and confirmation | Selected NCI and current NHS clinical education | Institutional routes traced; page, expert and study payments unclosed. | Prompt specific assessment; no home diagnostic threshold. |
| APL distinction | Selected adult professional PDQ passages | Specific member interests and original trials not fully cleared. | Urgent specialist context; no personal treatment instruction. |
| Treatment families and follow-up | September 2026 NHS care information | National website funding policy is dated; underlying trial finance unclosed. | Individual purpose and intensity; no independently ranked medicine. |
| Supplements and interactions | NCI diet and interaction cautions | Product-study finances remain unclosed. | No AML cure claim; actual ingredient/medicine review needed. |
What AML is: abnormal myeloid cells in blood and marrow
Abnormal myeloblasts can crowd out healthy blood-cell production. The consequences include anemia, impaired infection defense and bleeding. AML differs from acute lymphoblastic leukemia, which involves a lymphoid lineage. Rarely, AML-related cells form an extramedullary mass called a myeloid sarcoma or chloroma. Selected disease distinctions.
The full diagnostic name matters. A general “blood cancer” label does not establish which subtype is present or whether a particular medicine belongs in the plan. Keep the laboratory report available for appointments; the letters AML do not by themselves identify one identical disease course.
Symptoms: rapid change requires clinical assessment
Fatigue, pallor, breathlessness, infections, fever, unexplained bruising or bleeding, and bone or joint pain can occur. Changes may develop over weeks. These features overlap with other illnesses, so seek clinical assessment rather than diagnosing AML from a checklist. NHS AML symptom assessment.
New unexplained bleeding or a rapidly worsening illness deserves attention even when a previous test was reassuring. If someone is severely unwell, use local emergency services. A routine future appointment is not the right place to resolve an immediate emergency. Bring the time course of symptoms, recent results and medicines to the assessment.
Diagnosis: confirm the cells before selecting a pathway
The NHS describes blood testing and a bone-marrow sample, with further tests chosen according to the findings. Imaging or a lumbar puncture may be considered in selected situations; not everybody needs every investigation. NHS testing pathway.
Ask what the marrow and additional laboratory tests establish, which results are still pending, and who explains the final subtype. An internet blood-count threshold is not a substitute for that interpretation. Cancer-cell findings and inherited risks answer different questions; discuss whether any further family-risk assessment is relevant instead of assuming every abnormal cancer test is inherited.
Acute promyelocytic leukemia: a distinct urgent subtype
Acute promyelocytic leukemia (APL) is an AML subtype associated with PML::RARA, usually involving chromosomes 15 and 17. It can cause serious bleeding and clotting problems, requiring urgent specialist care. Its differentiating-treatment pathway differs from many other AML pathways. Selected APL context.
This distinction must come from clinical and laboratory assessment. Do not delay care while trying to identify the subtype yourself. Medicines such as all-trans retinoic acid and arsenic trioxide belong to supervised APL pathways; their mention does not authorize taking a supplement or a chemical product. The guide gives no regimen, dose or timing instruction. Specialist APL pathway.
Treatment families: intensity and purpose are individual decisions
AML care can include chemotherapy, selected targeted medicines and, for some people, a stem-cell transplant. Supportive treatment is part of care. The proposed intensity depends on the diagnosis, health and clinical circumstances. NHS treatment overview.
Ask the team to state the aim of the specific plan: remission, longer-term disease control, transplant preparation or symptom relief. “Less intensive” does not by itself describe one universal outcome or exclude every potential longer-term strategy. Age alone is not a treatment decision. This article does not rank products, infer superiority from an agency webpage or prescribe a drug combination.
Infection, neutropenia and urgent treatment-period concerns
Cancer or its treatment can lower infection-fighting neutrophils. Fever, chills or other signs of infection during treatment need prompt contact with the cancer team. Medicines that reduce fever can conceal the problem, so obtain the team’s advice. NCI infection precautions.
Keep a current emergency contact number and follow the team’s written instructions. Do not wait for the next routine appointment or substitute a supplement for assessment. A potentially serious infection needs clinical evaluation even if it seems minor at first. This page does not provide an individual temperature threshold, antibiotic course or home line-care procedure.
Interactions: check actual drugs, foods and ingredients
Some supplements and foods alter anticancer-drug exposure. NCI’s interaction summary includes St John’s wort and grapefruit among examples, with effects dependent on the actual medicine. Selected interaction context.
Give the oncology pharmacist ingredient labels and a full list of prescription medicines, nonprescription products, herbs, teas and powders. Report changes during treatment. “Natural” does not establish compatibility, but a general online warning is also not a universal prohibition on every fruit or vitamin. Do not stop a prescription or change a cancer dose without instructions from the responsible clinician.
Supportive care, nutrition and symptom relief
Supportive care may include treatment or prevention of infection, transfusions and selected blood-cell support. Care also addresses symptoms and comfort. Selected supportive-care roles.
Eating adequately and managing symptoms have a different purpose from treating leukemia. Tell the team about difficulty eating, weight change or a proposed restrictive diet. NCI’s diet information does not establish a marketed diet or supplement as a cancer cure. Diet and supplement limits. A dietitian can help plan intake around the person’s current needs; the article does not recommend fasting to “starve” leukemia.
Disease status and follow-up: ask what the next result means
AML does not use a standard solid-tumor stage sequence. NCI describes states such as newly diagnosed disease, remission, refractory disease and recurrence. Remission and a guarantee of permanent cure are different concepts. Selected disease-status framework.
Review continues during and after treatment; concerning symptoms should be reported between scheduled appointments. Follow-up context. Obtain one current plan showing the prescribed medicines, tests, result contacts and emergency number. If a prescription is missed, unavailable or causing a problem, ask the team how to proceed. No universal catch-up dose or monitoring interval is supplied here.
Supplements and laboratory findings: what the review establishes
This review establishes no independently cleared human benefit from a supplement treating AML. Nutrition support and correcting a medical deficiency should not be confused with a leukemia-treatment claim. Selected evidence boundary.
Cell and animal experiments do not alone establish improved survival or quality of life in patients. An outcome comparison requires the original patient population, comparator, follow-up, harms, funding and author interests. The underlying oncology trials were not exhaustively financially audited in this guide; no numerical efficacy ranking is inferred from institutional editorial review. Discuss a clinical trial through the treating team, using its actual protocol and sponsor disclosures.
Funding and source roles
Research funding at a glance
13 disclosure entries. The counts below summarize independence tiers explicitly assigned in this article. They count disclosures, not studies, funding amounts or evidence quality.
Consult this article’s source and funding notes for named funders, countries, relationships and exceptions where available. Institutional backing, researcher interests and trial sponsorship are separate questions. Public funding alone does not establish independence; commercial ties alone do not prove a claim false. This overview is not a new financial audit.
The source-specific map separates documented institutional funding from disease-page payments and trial sponsorship. Unknown allocations remain unknown. A public agency, charity or academic address does not by itself establish independent treatment efficacy.
| Source | Funding / backers | Country / jurisdiction | Independence | Credibility / incentives / gaps |
|---|---|---|---|---|
| NCI adult acute myeloid leukemia, patient PDQ | Congressional appropriations; separate gift routes. Page, contributor and underlying-study allocations unclosed. Patient text derives from the professional version. Dated outside advisory disclosures; no NCI page payment inferred. | United States; NCI/NIH/HHS, Bethesda, Maryland; federal jurisdiction. | Tier 3 clinical context — named reviewer has documented outside commercial ties; no independent outcome clearance. | C, provisional — selected clinical descriptions only. Patient summary derives from the professional version; dated outside relationships do not establish current contracts or NCI page sponsorship. Board recusal does not clear all supporting trials. |
| NCI adult AML, professional PDQ | Congressional appropriations; separate gift routes. Page, contributor and underlying-study allocations unclosed. Named lead reviewer: Aaron Gerds. Dated outside advisory disclosures; no NCI page payment inferred. | United States; NCI/NIH/HHS, Bethesda, Maryland; federal jurisdiction. | Tier 3 clinical context — named reviewer has documented outside commercial ties; no independent outcome clearance. | C, provisional — selected clinical descriptions only. Professional source names the reviewer; dated outside relationships do not establish current contracts or NCI page sponsorship. Board recusal does not clear all supporting trials. |
| NHS AML symptoms | National website funding policy states DHSC funding and no advertising/corporate sponsorship. Page and source-study allocations unclosed. | United Kingdom; national NHS patient website, distinct from individual provider trusts. | Tier 2 clinical context, provisional; underlying studies not financially cleared. | B, provisional — care accountability favors accuracy; reviewed 9 September 2026; next review due 9 September 2029. Simplification and contributor/study interests remain. |
| NHS AML tests and next steps | National website funding policy states DHSC funding and no advertising/corporate sponsorship. Page and source-study allocations unclosed. | United Kingdom; national NHS patient website, distinct from individual provider trusts. | Tier 2 clinical context, provisional; underlying studies not financially cleared. | B, provisional — care accountability favors accuracy; reviewed 9 September 2026; next review due 9 September 2029. Simplification and contributor/study interests remain. |
| NHS AML treatment | National website funding policy states DHSC funding and no advertising/corporate sponsorship. Page and source-study allocations unclosed. | United Kingdom; national NHS patient website, distinct from individual provider trusts. | Tier 2 clinical context, provisional; underlying studies not financially cleared. | B, provisional — care accountability favors accuracy; reviewed 9 September 2026; next review due 9 September 2029. Simplification and contributor/study interests remain. |
| NCI infection and neutropenia | Congressional appropriations; separate gift routes. Page, contributor and underlying-study allocations unclosed. | United States; NCI/NIH/HHS, Bethesda, Maryland; federal jurisdiction. | Tier 2 clinical context, provisional; underlying studies not financially cleared. | B, provisional — expert review and public accountability support accuracy; reviewed 23 January 2020; selected safety body read; Institutional mission and unclosed page/contributor interests remain. |
| NCI popular diets, supplements and cancer | Congressional appropriations; separate gift routes. Page, contributor and underlying-study allocations unclosed. | United States; NCI/NIH/HHS, Bethesda, Maryland; federal jurisdiction. | Tier 2 clinical context, provisional; underlying studies not financially cleared. | B, provisional — expert review and public accountability support accuracy; posted 30 October 2024; Institutional mission and unclosed page/contributor interests remain. |
| NCI cancer therapy–food/supplement interactions, patient PDQ | Congressional appropriations; separate gift routes. Page, contributor and underlying-study allocations unclosed. | United States; NCI/NIH/HHS, Bethesda, Maryland; federal jurisdiction. | Tier 2 clinical context, provisional; underlying studies not financially cleared. | B, provisional — expert review and public accountability support accuracy; updated 25 April 2024; PDQ board-specific interests are not fully published. Not a treatment guideline. |
| NCI budget and appropriations, May 2026 | Congressional funding through HHS/NIH. Enacted appropriations and future requests differ; no disease-page amount assigned. | United States; NCI/NIH/HHS, Bethesda, Maryland. | Tier 3 institutional financial self-report. | B, provisional — actual budget process and dated body read; fiscal accountability, budget priorities and missing page allocation. |
| NCI Gift Fund and contribution routes, August 2025 | Public gifts/Gift Fund and Breast Cancer Research Stamp route separate from Congress. Named page donors and complete accepted receipts unclosed. | United States; 9000 Rockville Pike, Bethesda, Maryland; federal NCI. | Tier 3 institutional financial self-report. | B, provisional — actual contribution and headquarters text read; no named donor control or page sponsorship inferred. |
| NCI PDQ editorial boards, November 2022 | NCI support; non-government member honoraria/travel expenses. Declarations and recusal required; specific conflicts not publicly required. | United States; NCI, Bethesda, with international board contributors. | Tier 3 institutional process and payment self-report. | B, provisional — actual dated policy read; editorial independence does not clear member interests or sponsored underlying trials. |
| NHS national content policy, October 2022 | DHSC funding; policy states no advertising or corporate sponsorship. Full page/expert receipts unclosed. | United Kingdom; national NHS website. | Tier 3 financial/editorial self-report. | B, provisional — actual funding/accuracy policy read; next review due October 2025 passed. Not a provider-trust accounts profile. |
| Annenberg 2023–2024 activity: dated Aaron Gerds disclosures | Activity supported by a GSK educational grant. Gerds lists advisory roles including AbbVie, CTI Biopharma, GSK, Kartos, Merck and PharmaEssentia. Amounts and current contracts unclosed. | United States; Annenberg Center, Rancho Mirage, California; named faculty affiliation Cleveland, Ohio. | Tier 4 — manufacturer-supported course, used only for original disclosure provenance. | D for sponsored clinical outcomes; own dated grant/relationship statement. Released 30 April 2023; credit closed 30 April 2024. No NCI page payment or sponsor control inferred. |
Frequently asked questions
Is AML the same as ALL? No. AML is myeloid disease; acute lymphoblastic leukemia is a different lymphoid disease family. The laboratory diagnosis matters.
Is APL a separate care pathway within AML? Yes. Its characteristic fusion and bleeding/clotting concerns make prompt subtype-specific care important; this page does not provide an APL regimen.
Can a blood test alone tell me which AML treatment I need? A specialist interprets blood, marrow and selected additional tests together. Ask for the final subtype and remaining investigations.
Does remission mean the same thing as permanent cure? No. Discuss the current disease status, further treatment and follow-up with the team.
Can supplements replace AML treatment? No independently cleared replacement benefit is established here. Disclose proposed ingredients and restrictive diets to the treating team.
Sources and funding notes
NCI adult patient AML summary updated 16 May 2025; professional summary updated 14 March 2025, with selected APL passages read. NHS AML symptom, test and treatment pages reviewed 9 September 2026, next review due 9 September 2029. Their simplified intensity/goal wording is not used as a universal rule. Numerical marrow definitions, historical survival estimates, personal doses, chemotherapy schedules and transplant-age cutoffs are excluded. NCI infection source reviewed 23 January 2020; diet page posted 30 October 2024; interaction PDQ updated 25 April 2024. Financial/process sources describe institutional routes, not page-level or trial clearance. Sources are concentrated in the United States and United Kingdom; local availability and pathways vary.
- NCI adult acute myeloid leukemia, patient PDQ — Selected disease identity and disease-status framework; no marrow cutoff or prognosis estimate.
- NCI adult AML, professional PDQ — Selected APL fusion and urgent bleeding context; historical schedules/outcome estimates excluded.
- NHS AML symptoms — Rapid symptom development and prompt clinical assessment; symptoms do not diagnose AML.
- NHS AML tests and next steps — Blood and marrow assessment and selected additional tests; not a universal testing schedule.
- NHS AML treatment — Selected treatment families and supportive/follow-up roles; simplified intensity labels not treated as universal goals.
- NCI infection and neutropenia — Treatment-period infection safety; no personal fever or antibiotic protocol.
- NCI popular diets, supplements and cancer — Nutrition versus cancer-treatment claims, not AML supplement-effect evidence.
- NCI cancer therapy–food/supplement interactions, patient PDQ — Selected ingredient and food interaction precautions; no universal food prohibition.
- NCI budget and appropriations, May 2026 — Institutional appropriation route only.
- NCI Gift Fund and contribution routes, August 2025 — Separate gift route and office identity; no clinical evidence.
- NCI PDQ editorial boards, November 2022 — Board independence, honoraria and conflict-disclosure scope.
- NHS national content policy, October 2022 — Website funding and editorial safeguards only.
- Annenberg 2023–2024 activity: dated Aaron Gerds disclosures — Financial provenance only; no course treatment claims used.
Educational research reviewed 4 October 2026. Diagnosis and treatment require a qualified clinician; this article does not provide an individual prescription or replace urgent assessment.
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.